Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vimgreen Starts Phase II Trial of A2AR Antagonist for Parkinson’s

publication date: Aug 15, 2024

Hangzhou Vimgreen Pharma has enrolled 150 Parkinson’s Disease patients in a China Phase II trial of VG081821AC, a novel adenosine A2A receptor (A2AR) antagonist. The candidate also functions as an inverse A2AR agonist. 150 participants with early-to-mid stage Parkinson's disease were randomized into one of three cohorts: high-dose, low-dose and placebo at a ratio of 1:1:1. Vimgreen develops drugs that are based on the modulation of adenosine signaling. Most Parkinson’s therapies use dopamine to treat the symptoms of disease, but Vimgreen’s candidate aims to avoid, decrease or delay motor complications in early stage PD. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here